...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: No data, No communication,,no interest!!

Happy New Year narmac and all.

I just noticed something interesting on your post. See below. ZCC lists the top guy at ZCC by name (the acting CEO IMO) and RVX, a publicly traded company does not even provide Chris' name and title. Go figure?

Contact

ZCC

Sanjay Lakhotia, Ph.D., MBA
Chief Business Officer
E: [email protected]
T: 1 (587) 390-7865

 

The contact info for RVX is

Head Office
300, 4820 Richard Road SW
Calgary, AB, CANADA, T3E 6L1
Phone 403.254.9252
Fax 403.256.8495
[email protected] 
Head Office Map

 

It is remarkable that Dr Lakhotia has made continuous progress with zen3694

at ZCC and yet RVX has made ZERO progress with apabetalone in years.

 

Just having some fun watching paint dry on a Friday.

 

Cheers

Toinv

Share
New Message
Please login to post a reply